- Home
- DSP vs CGEN Comparison
DSP vs CGEN Comparison
Compare DSP & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- CGEN
- Stock Information
- Founded
- DSP 1999
- CGEN 1993
- Country
- DSP United States
- CGEN Israel
- Employees
- DSP N/A
- CGEN N/A
- Industry
- DSP EDP Services
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DSP Technology
- CGEN Health Care
- Exchange
- DSP Nasdaq
- CGEN Nasdaq
- Market Cap
- DSP 142.1M
- CGEN 125.3M
- IPO Year
- DSP 2021
- CGEN 2000
- Fundamental
- Price
- DSP $8.62
- CGEN $1.79
- Analyst Decision
- DSP Strong Buy
- CGEN
- Analyst Count
- DSP 9
- CGEN 0
- Target Price
- DSP $20.44
- CGEN N/A
- AVG Volume (30 Days)
- DSP 329.3K
- CGEN 377.6K
- Earning Date
- DSP 11-11-2025
- CGEN 11-11-2025
- Dividend Yield
- DSP N/A
- CGEN N/A
- EPS Growth
- DSP N/A
- CGEN N/A
- EPS
- DSP 0.13
- CGEN N/A
- Revenue
- DSP $318,471,000.00
- CGEN $22,144,000.00
- Revenue This Year
- DSP $16.44
- CGEN N/A
- Revenue Next Year
- DSP $15.32
- CGEN $208.08
- P/E Ratio
- DSP $64.51
- CGEN N/A
- Revenue Growth
- DSP 30.92
- CGEN N/A
- 52 Week Low
- DSP $8.19
- CGEN $1.13
- 52 Week High
- DSP $26.33
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- DSP 37.04
- CGEN 69.94
- Support Level
- DSP $8.19
- CGEN $1.30
- Resistance Level
- DSP $8.85
- CGEN $1.82
- Average True Range (ATR)
- DSP 0.40
- CGEN 0.11
- MACD
- DSP 0.04
- CGEN 0.05
- Stochastic Oscillator
- DSP 29.05
- CGEN 94.23
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.